Proteflazid® effectiveness for prevention and treatment of acute viral respiratory infections in the conditions of COVID-19.

Unlabelled: The original antiviral drug Proteflazid® has been used in clinical practice since the early 2000s for the etiotropic treatment of acute respiratory viral diseases, due to its property of blocking viral RNA and DNA polymerases. Considering that at the beginning of the global COVID- 19 pandemic, caused by RNA-containing virus of SARS-CoV-2 species in 2020, the ability of the drug active substance to inhibit the activity of 3CL- protease of the SARS-CoV-2 coronavirus was shown by molecular docking and, subsequently, to confirm the property of the active substance to block the reproduction of the SARS-CoV-2 virus in cell cultures in vitro. It was extremely important to test the effectiveness of the drug Proteflazid, drops for the prevention and treatment of COVID-19 disease at "off labell use".

Tris(μ-2-meth-oxy-6-{[(2-sulfido-eth-yl)imino]meth-yl}phenolato)trinickel(II) di-methyl-formamide monosolvate: crystal structure, spectroscopic characterization and anti-bacterial activity.

The title trinuclear nickel(II) complex, [Ni(CHNOS)]·CHNO, with a Schiff base ligand formed from 2-amino-ethane-thiol and -vanillin crystallizes in the ortho-rhom-bic space group . Its asymmetric unit consists of one neutral Ni mol-ecule and one DMF solvent mol-ecule. The solid-state organization of the complex can be described as an insertion of the solvent mol-ecules within the crystallographically independent trinuclear Ni species.

PROTEFLAZID®: clinical studies as evidence base of its antiviral activity.

The article contains the results of many years of clinical studies of efficiency and safety of the preparation Proteflazid®, obtained from the wild cereals Deschampsia caespitosa L. and Calamagrotis epigeios L. Proteflazid® has direct antiviral and anti-relapsing effects in various disease of viral etiology, registered in more than 230 clinical studies.

Proteflazid®: treatment of herpesvirus and mixed infections. Meta-analysis of clinical trials results.

Unlabelled: There is a meta-analysis of clinical trials results concerning the evaluation of efficiency of the drug Proteflazid® (drops) in the treatment of adult patients with herpesvirus and mixed infections.

Aim: Objective of the study: to evaluate the clinical efficacy of the drug Proteflazid® in a treatment of herpesvirus (HSV-1, HSV-2) and mixed infections in adults by meta-analysis of clinical trials.

Materials And Methods: In meta-analysis, 16 scientific sources with results of controlled studies with participation of 1336 patients over 18 y.